Results 11 to 20 of about 168,427 (273)

Immunogenicity of two different dosages (10 and 5 μg) of recombinant DNA hepatitis B vaccine in healthy neonates [PDF]

, 1994
The immunogenicity of a half (5 μg) and a full (10 μg) dosage of recombinant DNA yeast-derived hepatitis B vaccine (HB-Vax-DNA) in healthy neonates was assessed in order to compare two candidate dosages of vaccine.
Del Cancho, R. (R.), Grosheie, P.M. (P.), Heijtink, R.A. (Rudolf), Huisman, W. (Willem), Schalm, S.W. (Solko), Voogd-Schotanus, M. (M.)   +5 more
core   +8 more sources

Knowledge and associated factors for the uptake of hepatitis B vaccine among nonmedical undergraduate students in a private university in Ekiti State, Nigeria

Nigerian Journal of Medicine, 2022
Background: Hepatitis B is a life-threatening viral infection that causes acute and chronic diseases of the liver. Hepatitis B infection is endemic in Nigeria with a national pooled prevalence rate of 9.5%.
Olusegun Elijah Elegbede, Ayodele Kamal Alabi, Taiye Adeyanju Alao, Taofeek Adedayo Sanni   +3 more
doaj   +1 more source

Inspiration to mRNA-based COVID-19 vaccination: Serious adverse case reports with hepatitis B vaccine in real-world

Frontiers in Pediatrics, 2022
ObjectivesThe hepatitis B vaccine comprises hepatitis B surface antigen (HBsAg) produced by transgenic yeast cells. There are few serious adverse events (SAE) reports after Hepatitis B vaccination.MethodsThe authors searched the Chinese legal documents ...
Jinmiao Lu, Xunjie Zhang, Hong Xu, Zhiping Li   +3 more
doaj   +1 more source

Predictions of the emergence of vaccine-resistant hepatitis B in The Gambia using a mathematical model [PDF]

, 2000
Vaccine escape variants of hepatitis B virus (HBV) have been identified world-wide. A mathematical model of HBV transmission is used to investigate the potential pattern of emergence of such variants.
Carman, W. (William), Nokes, D. James, Wilson, J. N.   +2 more
core   +6 more sources

Effect of a Community-Based Hepatitis B Virus Infection Detection Combined with Vaccination Program in China

Vaccines, 2021
Evidence on the effectiveness of hepatitis B virus (HBV) infection screening and vaccination programs remains rare in China. We used a quasi-experimental method, propensity score matching, to evaluate the effects of a community-based HBV infection ...
Xinyao Liu, Wuqi Qiu, Yan Liang, Wei Zhang, Qian Qiu, Xinxin Bai, Guolin Dai, Hao Ma, Hongpu Hu, Wei Zhao, Guangyu Hu   +10 more
doaj   +1 more source

Antibody levels and protection after Hepatitis B vaccine in adult vaccinated healthcare workers in northern Uganda.

PLoS ONE, 2022
Hepatitis B vaccine has contributed to the reduction in hepatitis B virus infections and chronic disease globally. Screening to establish extent of vaccine induced immune response and provision of booster dose are limited in most low-and-middle income ...
Moses Ocan, Moses Ocan, Frances Acheng, Carol Otike, Judith Beinomugisha, David Katete, Celestino Obua   +6 more
doaj   +2 more sources

Effectiveness of hepatitis B hyperimmunglobulin and vaccine in preventing perinatal transmission in children born from a mother with chronic B hepatitis

Zdorovʹe Rebenka, 2021
Background. Viral hepatitis is still one of the important health problems all over the world today. Hepatitis B is a life-threatening liver infection that can cause chronic infections.
Feyza Gökben Kahveci, Hasret Ayyildiz Civan, Özgül Salihoğlu   +2 more
doaj   +1 more source

Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen

Nature Communications, 2022
The hepatitis B vaccine is recognised as the most effective approach in reducing hepatitis-B-related morbidity; vaccine-escape mutations are however capable of infecting vaccinated individuals. In this work, authors aim to establish a hepatitis B vaccine
Ayaka Washizaki, Asako Murayama, Megumi Murata, Tomoko Kiyohara, Keigo Yato, Norie Yamada, Hussein Hassan Aly, Tomohisa Tanaka, Kohji Moriishi, Hironori Nishitsuji, Kunitada Shimotohno, Yasumasa Goh, Ken J. Ishii, Hiroshi Yotsuyanagi, Masamichi Muramatsu, Koji Ishii, Yoshimasa Takahashi, Ryosuke Suzuki, Hirofumi Akari, Takanobu Kato   +19 more
doaj   +1 more source

Randomized, Controlled Trial of the Long Term Safety, Immunogenicity and Efficacy of RTS,S/AS02(D) Malaria Vaccine in Infants Living in a Malaria-Endemic Region. [PDF]

, 2013
The RTS,S/AS malaria candidate vaccine is being developed with the intent to be delivered, if approved, through the Expanded Programme on Immunization (EPI) of the World Health Organization.
A Olotu, Ali Mohammed, Amanda Leach, B Lell, David Schellenberg, E Macete, EV Macete, Francisca Machera, Grace Mwangoka, Hassan Mshinda, J Sacarlal, J Sacarlal, JJ Aponte, Joe Cohen, Johan Vekemans, KA Bojang, KE Kester, KP Asante, Marc Lievens, Marcel Tanner, Marie-Claude Dubois, MedDRA, MT White, Mwanajaa Shomari, Nahya Salim, Omar Juma, P Aide, P Aide, P Bejon, Richard Kamata, S Abdulla, S Owusu-Agyei, Salim Abdulla, ST Agnandji, ST Agnandji, ST Agnandji, Sulende Kubhoja, Terrell Carter, Thomas Aebi, Tonya Villafana, W Ripley Ballou, WHO, WHO, WHO/IVR   +43 more
core   +5 more sources

Hepatitis B vaccine development and implementation

Human Vaccines & Immunotherapeutics, 2020
Vaccination against hepatitis B is the most effective strategy to control HBV infection. The first licensed hepatitis B vaccine was developed by the purification of hepatitis B surface antigen (HBsAg) from plasma of asymptomatic HBsAg carriers. Then, the
Hong Zhao, Xiaoying Zhou, Yi-Hua Zhou
doaj   +1 more source